Targets › SLC5A2
32 programs from 32 companies in 258 trials: 86 Phase 4, 78 Phase 2, 52 Phase 3, 42 Phase 1; Metabolic and endocrine, Cardiovascular, Oncology; next expected readout Nov 2026.
Electrogenic Na(+)-coupled sugar symporter that actively transports D-glucose at the plasma membrane, with a Na(+) to sugar coupling ratio of 1:1. Transporter activity is driven by a transmembrane Na(+) electrochemical gradient set by the Na(+)/K(+) pump. (UniProt, P31639)
Open in Phaseline: the race on SLC5A2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Brigham and Women's Hospital | MIB 626 (NMN) Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC5A2, SLC6A2, GLP1R, UNKNOWN, Tubulin, OPRM1, NR3C2, AGTR1, IL4R, SLC6A4, HTR2A, HTR2C | Phase 4 | Prostate Cancer; Stable Coronary Disease; Allergic Contact Dermatitis; Hypertension … | Nov 2026 |
| Zhujiang Hospital | Henagliflozein SGLT2 inhibitor | SLC5A2 | Phase 4 | Type2 Diabetes Mellitus | Nov 2026 |
| Yonsei University | Enavogliflozin SGLT2 inhibitor | SLC5A2 | Phase 4 | Nonobstructive Hypertrophic Cardiomyopathy; Atrial Fibrillation; Diabetes Mellitus, Type 2 | Nov 2026 |
| AstraZeneca | Dapagliflozin Sodium/glucose cotransporter 2 inhibitor | SLC5A2 | Phase 4 | Chronic Kidney Disease; Heart Failure and Impaired Kidney Function; Chronic Kidney Disease and Hypertension; Type 2 Diabetes Mellitus … | Dec 2026 |
| Children's Hospital Medical Center, Cincinnati | SGLT-2 inhibitor SGLT-2 inhibitor | SLC5A2 | Phase 4 | Diabetes Mellitus, Type 2 | Dec 2026 |
| JW Pharmaceutical | Empagliflozin Sodium/glucose cotransporter 2 inhibitor | SLC5A2 | Phase 4 | Type 2 Diabetes Mellitus (T2DM) | Mar 2027 |
| Odense University Hospital | Dapagliflozin Propanediol Sodium/glucose cotransporter 2 inhibitor | SLC5A2 | Phase 4 | Kidney Transplantation Recipients | Jun 2027 |
| Yale University | Bexagliflozin Sodium/glucose cotransporter 2 inhibitor | SLC5A2 | Phase 4 | Sleep Apnea | Sep 2027 |
| University of Michigan | Canagliflozin Sodium/glucose cotransporter 2 inhibitor | SLC5A2 | Phase 4 | Type 2 Diabetes | Dec 2027 |
| Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Henagliflozin SGLT2 inhibitor | SLC5A2 | Phase 4 | Diabetes Mellitus, Type 2 | Dec 2027 |
| Hangzhou Zhongmei Huadong Pharmaceutical | ganagliflozin SGLT-2 inhibitor | SLC5A2 | Phase 4 | T2DM (Type 2 Diabetes Mellitus) | Dec 2027 |
| National Heart Centre Singapore | SGLT2 Inhibitor Sodium glucose cotransporter 2 inhibition | SLC5A2 | Phase 4 | Diabetes Mellitus | Jun 2034 |
| Fudan University | Canagliflozin Sodium/glucose cotransporter 2 inhibitor | SLC5A2 | Phase 4 | Type 2 Diabetes Mellitus | – |
| Boryung Pharmaceutical | Dapagliflozin Sodium/glucose cotransporter 2 inhibitor | SLC5A2 | Phase 4 | Type 2 Diabetes; Diabetes Mellitus; Diabete Mellitus | – |
| Getz Pharma | Ertugliflozin Sodium/glucose cotransporter 2 inhibitor | SLC5A2 | Phase 4 | Liver Fat; Heart Failure; Ketones, Metabolism | – |
| Samsung Medical Center | SGLT2 inhibitor Sodium-glucose cotransporter 2 inhibitor | SLC5A2 | Phase 4 | Acute Myocardial Infarction | – |
| Amsterdam UMC, location VUmc | ertugliflozine SGLT2 inhibitor | SLC5A2 | Phase 4 | Type 2 Diabetes | – |
| THPharm | Dapagliflozin (THP-00101) Sodium/glucose cotransporter 2 inhibitor | SLC5A2 | Phase 3 | Type 2 Diabetes | Dec 2026 |
| Boehringer Ingelheim | Empagliflozin Sodium/glucose cotransporter 2 inhibitor | SLC5A2 | Phase 3 | Chronic Kidney Disease; Heart Failure; Healthy; Diabetes … | Dec 2026 |
| Lexicon Pharmaceuticals | Sotagliflozin Sodium/glucose cotransporter 1 inhibitor; Sodium/glucose cotransporter 2 inhibitor | SLC5A1, SLC5A2 | Phase 3 | Obstructive Cardiomyopathy, Hypertrophic; Diabetic Nephropathies; Cardiovascular Diseases; Type 1 Diabetes | Jan 2027 |
| Prof. Dr. med. Ingo Eitel | SGLT2 SGLT2 inhibitor | SLC5A2 | Phase 3 | Atrial Hypertension | May 2032 |
| Dong-A ST | DA5221-T SGLT-2 inhibitor | SLC5A2 | Phase 3 | Type 2 Diabetes | – |
| Ottawa Heart Institute Research Corporation | Canagliflozin Sodium/glucose cotransporter 2 inhibitor | SLC5A2 | Phase 2 | Diabetes Type 2 | Dec 2026 |
| University of Colorado, Denver | canagliflozin Sodium/glucose cotransporter 2 inhibitor | SLC5A2 | Phase 2 | Type 2 Diabetes | Dec 2026 |
| National Taiwan University Hospital | canagliflozin Sodium/glucose cotransporter 2 inhibitor | SLC5A2 | Phase 2 | Acute Kidney Injury | Jul 2027 |
| Memorial Sloan Kettering Cancer Center | Canagliflozin Sodium/glucose cotransporter 2 inhibitor | SLC5A2 | Phase 2 | Breast Cancer | Oct 2027 |
| McGill University Health Centre/Research Institute of the McGill University Health Centre | Canagliflozin Sodium/glucose cotransporter 2 inhibitor | SLC5A2 | Phase 2 | ESRD; ESRD, CKD Stage 4, CKD Stage 5 | Feb 2028 |
| Minneapolis Heart Institute Foundation | SGLT2 inhibitor Sodium glucose co-transporter 2 inhibitor | SLC5A2 | Phase 2 | Heart Attack | Dec 2028 |
| University of Maryland, Baltimore | Canagliflozin Sodium/glucose cotransporter 2 inhibitor | SLC5A2 | Phase 1 | Diabetes Mellitus, Type 2 | Dec 2026 |
| Jonsson Comprehensive Cancer Center | Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside SGLT2-targeting radioactive glucose tracer for PET imaging | SLC5A2 | Phase 1 | Lung Adenocarcinoma | Oct 2027 |
| University of Virginia | Bexagliflozin Sodium/glucose cotransporter 2 inhibitor | SLC5A2 | Phase 1 | Angina Patients With Non-obstructive Coronary Artery Disease | Oct 2027 |
| West China Hospital | Canagliflozin Sodium/glucose cotransporter 2 inhibitor | SLC5A2 | Phase 1 | Colorectal Cancer; Solid Tumor | Jul 2028 |
Type 2 Diabetes (13) Heart Failure (9) Chronic Kidney Diseases (7) Breast Cancer (6) Diabetes Mellitus, Type 2 (6) Diabetes Mellitus (5) Acute Kidney Injury (4) Type 2 Diabetes Mellitus (T2DM) (4) Obstructive Sleep Apnea (4) Chronic Kidney Disease and Hypertension (3) Type 2 Diabetes Mellitus (3) Obesity (3)
small molecule (30), mixed (2)
THPharm (1) West China Hospital (1) Boryung Pharmaceutical (1) AstraZeneca (1) Lexicon Pharmaceuticals (1) University of Virginia (1) Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (1) Prof. Dr. med. Ingo Eitel (1) Jonsson Comprehensive Cancer Center (1) Samsung Medical Center (1) Yonsei University (1) Getz Pharma (1) Boehringer Ingelheim (1) Brigham and Women's Hospital (1) McGill University Health Centre/Research Institute of the McGill University Health Centre (1) University of Michigan (1) University of Maryland, Baltimore (1) Ottawa Heart Institute Research Corporation (1) Dong-A ST (1) Zhujiang Hospital (1)
SLC5A1 (1) SLC6A2 (1) GLP1R (1) UNKNOWN (1) Tubulin (1) OPRM1 (1) NR3C2 (1) AGTR1 (1) IL4R (1) SLC6A4 (1) HTR2A (1) HTR2C (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.